Business Parks & Science Centres



Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Person › Details

Franz Wocheslander (Bayern Kapital Risikokapitalbeteiligungs GmbH)

Wocheslander, Franz (Bayern Kapital 201112 Investment Manager)


Organisation Organisation Bayern Kapital Risikokapitalbeteiligungs GmbH
  Group Bavaria (govt region)
Products Product venture capital
  Product 2 medical device

High-Tech Gründerfonds Management GmbH. (12/22/11). "Press Release: Eyesight & Vision GmbH. High-Tech Gründerfonds and Bayern Kapital Invest in Technology for Improved Cataract Eye Surgery". Nürnberg.

Eyesight & Vision GmbH, a specialist in intraoperative aberrometry equipment, has successfully completed a first round of financing with High-Tech Gründerfonds and SeedFonds Bayern. This is intended to make the patented Eyesight & Vision technology ready for market introduction.

Eyesight & Vision GmbH develops and markets diagnostic equipment for refractive eye surgery, i.e. for operations in which the overall refractive power of the eye is changed. The equipment is the first to perform real-time measurement of the refractive power of the eye during cataract surgery and provide the surgeon with information in situ concerning the position, centring and refractive power of the intraocular lens (IOL).

With the currently conventional method: measuring refractive error before and after the operation, more than 20% of all patients continue to have defective vision after the procedure. This is 160,000 patients in Germany alone. Eyesight & Vision's new real time measurement can drastically lower this rate, significantly improving the quality of the procedure. The "IntraOperative Wavefront Analyser", referred to as I-O-W-A®, which can be easily retrofitted to all conventional operating microscopes, helps approx. 800,000 cataract patients a year in Germany to regain a substantial part of their quality of life. It also makes precise alignment of the lens easier for the surgeon.

Dr. Matthias Dill, investment manager of High-Tech Gründerfonds and Franz Wocheslander, investment manager at Bayern Kapital, emphasized: "The technology from Eyesight & Vision has the potential to become a standard in all cataract operations."

"We are very happy that this financing will allow us to rapidly advance the development of our diagnostic equipment to market readiness," said Kurt Heiberger, founder and Managing Director of Eyesight & Vision GmbH. "We will continue to rely on coaching from Netzwerk Nordbayern's Dr. Hatz and on the network of our investors, Bayern Kapital and High-Tech Gründerfonds."

About Eyesight & Vision GmbH

Eyesight & Vision GmbH was founded by Kurt Heiberger and Andreas Schnalke in June 2010. Thomas Perl, Managing Director in charge of sales and a marketing expert for ophthalmologic diagnostic equipment has reinforced the team since 1st October 2011. The specialists who since 1999 have been involved in the optimal and rapid measurement of visual impairments have combined the advantages of the Tschering aberrometer and those of the Hartmann-Shack wavefront sensor in the patented Eyesight & Vision technology. The company develops and markets intraoperative real time aberrometry equipment for use in refractive eye surgery.

Eyesight & Vision GmbH
Kurt Heiberger
Neumeyerstr. 48
90411 Nuremberg
Phone: +49 (0)911-80 19 84 01
Fax: +49 (0)911-80 19 84 00

About Bayern Kapital

Bayern Kapital was set up in 1995 as an initiative of the Bavarian state government, aimed in particular at providing venture capital to young, innovative Bavarian companies. To date, Bayern Kapital has invested about €170 m in over 205 innovative, high-tech companies. Bayern Kapital is available as a contact for businesses in the region and currently manages an overall fund volume of about € 200 m.

Bayern Kapital GmbH
Franz Wocheslander
Laendgasse 135 a
D-84028 Landshut
Tel: +49 871 92325-0
Fax: +49 871 92325-55

About High-Tech Gründerfonds

High-Tech Gründerfonds invests venture capital in promising technology start-ups that transform promising research into viable business models. The seed financing provided is designed to enable start-ups to take an F&E idea through prototyping or a "proof of concept" and to market launch. Typically, High-Tech Gründerfonds invests €500,000 in the seed stage, with the potential for up to a total of €2 m per company. Investors in this public/private partnership include the Federal Ministry of Economics and Technology, the KfW Banking Group, as well as twelve industrial groups of ALTANA, BASF, B. Braun, Robert Bosch, CEWE Color, Daimler, Deutsche Post DHL, Deutsche Telekom, Qiagen, RWE Innogy, Tengelmann and Carl Zeiss. High-Tech Gründerfonds has about €560.5 m under management (€272 m for Fund I, €288.5 m Fund II).

High-Tech Gründerfonds Management GmbH
Dr. Matthias Dill
Ludwig-Erhard-Allee 2
53175 Bonn
Phone: +49 (228) 823 001-07
Fax: +49 228 823 000-50

Record changed: 2017-04-09


Picture [LSUS] – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px

» top